Cross-Reactive Neutralizing Human Domain Antibody Against HIV-1The invention describes the first identified anti-HIV human domain antibody (m36), which can potentially be used alone or synergistically with other anti-HIV antibodies and antiretroviral drugs as a therapeutic and/or preventative for HIV infection. It targets an epitope whose exposure is enhanced by binding of the HIV receptor CD4 to the HIV envelope glycoprotein (Env). M36 was identified by sequential panning of a newly developed large human VH library against Envs from different HIV-1 isolates. The antibody can neutralize HIV-1 primary isolates from different clades at low (nM) concentrations and due to its small size (14 kDa) is potentially able to efficiently penetrate lymphoid tissues where the virus replicates. The antibody is fairly well characterized and the inventors are generating derivatives of this antibody to improve the half-life and increase its potency and cross-reactivity.
Source:
Cross-Reactive Neutralizing Human Domain Antibody Against HIV-1Linkback:
https://tubagbohol.mikeligalig.com/index.php?topic=65262.0
Topic: Science News: Cross-Reactive Neutralizing Human Domain Antibody Against HIV-1 (Read 332 times)